Treatment of Well-Differentiated Gastric Neuroendocrine Tumor (NET) of the Gastrointestinal Tract
Clinical Scenario
This protocol applies to patients with a well-differentiated gastric neuroendocrine tumor (NET) of the gastrointestinal tract. This classification is distinct from poorly differentiated neuroendocrine carcinoma (NEC) — the two entities carry different management pathways and prognoses.
Classification Context
Current WHO classification of neuroendocrine neoplasms (NENs) separates well-differentiated NETs from poorly differentiated NECs. Confirming this distinction is essential before selecting a management approach, as treatment decisions differ substantially between the two categories.
Treatment Approach (Partial Overview)
Management is guided by local therapy directed at the gastric primary, with the specific surgical indication and approach selected according to an established classification system. Endoscopic treatment may also be considered. For disease involving the liver, additional interventional approaches are available.
Full regimen details, selection criteria, and complete clinical algorithm available in the structured protocol →
References
DOI: 10.1007/s00535-021-01827-7
- The WHO Classification of Endocrine Organs (2017) and Digestive System (2019) categorizes NENs as well-differentiated NENs (termed "NETs") or poorly differentiated NECs.
- For gastric NENs, the decision on surgical indications and selection of a surgical procedure according to Rindi's classification is recommended.
- Resection is indicated for NETs when feasible; endoscopic treatment can also be considered for gastrointestinal NETs.
- Moreover, radiofrequency ablation and transarterial chemoembolization are used for liver metastases.
View source ↗